Vir Biotechnology, Inc. (VIR)
| Market Cap | 3.01B |
| Revenue (ttm) | 2.33B |
| Net Income (ttm) | 1.22B |
| Shares Out | 132.38M |
| EPS (ttm) | 3.96 |
| PE Ratio | 5.73 |
| Forward PE | 7.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 919,849 |
| Open | 22.32 |
| Previous Close | 23.09 |
| Day's Range | 22.14 - 23.06 |
| 52-Week Range | 18.21 - 58.00 |
| Beta | -0.97 |
| Analysts | Buy |
| Price Target | 65.28 (+187.5%) |
| Earnings Date | May 5, 2022 |
About VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of He...
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for VIR stock is "Buy." The 12-month stock price forecast is 65.28, which is an increase of 187.45% from the latest price.
News
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20, 2022...
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty
Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc (NASDA...
Vir Biotechnology, Inc. (VIR) Q1 Earnings and Revenues Beat Estimates
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 19.94% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
– $1.2 billion of sotrovimab collaboration revenue recognized in the first quarter –
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline
Recently, Vir Biotechnology Inc (NASDAQ: VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ: ALNY),...
Vir Biotechnology, Inc. (VIR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and H...
– Strategic clinical program for hepatitis B and D with potential for multiple value drivers in 2022 –
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR
NEW YORK , April 23, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("VIR" or the "Company") (NASDAQ: VIR). Such investors are advised to c...
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter end...
4 Undervalued Biotech Stocks to Add to Your Buy List
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day
SAN FRANCISCO, April 13, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will host a virtual Hepatitis Portfolio R&D Day for the investment community on W...
3 Pharmaceutical Stocks With Awesome Futures
The market is so pessimistic about anything COVID-related that everything has gotten super cheap.
Antibody Treatments for COVD-19 Face Challenges in the U.S.
With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a la...
VIR Stock Down on Another Setback for COVID-19 Antibody
VIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
SAN FRANCISCO, April 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that a team of three company scientists were named one of the winners of the Pediatric COVID-19 Da...
Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the 21st Annual Needham Healthcare Confere...
Why Shares of Vir Biotechnology Rose 20.4% This Week
Joining the S&P SmallCap 600 could boost the company's profile.
Vir Biotechnology, Inc. (VIR) Moves 14.8% Higher: Will This Strength Last?
Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...
VIR Stock Gains on News of Inclusion in the S&P SmallCap 600
Vir Biotechnology (VIR) shares gain as the company is set to join the S&P SmallCap 600 effective prior to the opening of trading on Monday, Apr 4.
Vir Jumps 20% On S&P SmallCap 600 News
Currently, 66 ETFs are affected, but it will be added to even more funds soon.
Why Vir Biotechnology Stock Is Skyrocketing Today
The S&P SmallCap 600 index will soon include Vir.
Vir's stock is up 12% after news it will join the S&P SmallCap 600
Shares of Vir Biotechnology Inc. VIR, +15.99% were up 12.8% in premarket trading on Wednesday, the day after it was announced that the stock will join the S&P SmallCap 600 SML, -0.20% , effective April ...
These 2 Nasdaq Biotech Stocks Are Soaring Wednesday Morning
Markets looked to take a breather after a huge surge in recent weeks.
Camden Property Trust Set to Join S&P 500; Matador Resources to Join S&P MidCap 400; Vir Biotechnology to Join S&P Sm...
NEW YORK , March 29, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Camden Property Trust (NYSE: CPT) will replace People's United Financial Inc. (NASD: PBCT) in the S&P 500, S&P SmallCap 600 constitue...